Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 324

1.

Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.

Yvan-Charvet L, Matsuura F, Wang N, Bamberger MJ, Nguyen T, Rinninger F, Jiang XC, Shear CL, Tall AR.

Arterioscler Thromb Vasc Biol. 2007 May;27(5):1132-8. Epub 2007 Feb 22.

2.

The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport.

Tchoua U, D'Souza W, Mukhamedova N, Blum D, Niesor E, Mizrahi J, Maugeais C, Sviridov D.

Cardiovasc Res. 2008 Mar 1;77(4):732-9. Epub 2007 Dec 4.

PMID:
18056760
3.

HDL metabolism and CETP inhibition.

Barkowski RS, Frishman WH.

Cardiol Rev. 2008 May-Jun;16(3):154-62. doi: 10.1097/CRD.0b013e31816a3b60.

PMID:
18414186
4.

Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits.

Morehouse LA, Sugarman ED, Bourassa PA, Sand TM, Zimetti F, Gao F, Rothblat GH, Milici AJ.

J Lipid Res. 2007 Jun;48(6):1263-72. Epub 2007 Feb 26.

5.

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.

Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ.

N Engl J Med. 2004 Apr 8;350(15):1505-15.

6.

Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.

Hansen MK, McVey MJ, White RF, Legos JJ, Brusq JM, Grillot DA, Issandou M, Barone FC.

J Cardiovasc Pharmacol Ther. 2010 Jun;15(2):196-202. doi: 10.1177/1074248410362891. Epub 2010 Mar 23.

PMID:
20332533
7.

The effects of cholesterol ester transfer protein inhibition on cholesterol efflux.

Tall AR.

Am J Cardiol. 2009 Nov 16;104(10 Suppl):39E-45E. doi: 10.1016/j.amjcard.2009.09.018.

PMID:
19895943
8.

Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib.

Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, Magnus-Aryitey G, Cosgrove PG, Sand TM, Wester RT, Williams JA, Perlman ME, Bamberger MJ.

Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):490-7. Epub 2004 Jan 22.

10.

Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.

Yvan-Charvet L, Kling J, Pagler T, Li H, Hubbard B, Fisher T, Sparrow CP, Taggart AK, Tall AR.

Arterioscler Thromb Vasc Biol. 2010 Jul;30(7):1430-8. doi: 10.1161/ATVBAHA.110.207142. Epub 2010 May 6.

11.

Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism.

Millar JS, Brousseau ME, Diffenderfer MR, Barrett PH, Welty FK, Cohn JS, Wilson A, Wolfe ML, Nartsupha C, Schaefer PM, Digenio AG, Mancuso JP, Dolnikowski GG, Schaefer EJ, Rader DJ.

J Lipid Res. 2008 Mar;49(3):543-9. Epub 2007 Nov 21.

12.

Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.

Vergeer M, Bots ML, van Leuven SI, Basart DC, Sijbrands EJ, Evans GW, Grobbee DE, Visseren FL, Stalenhoef AF, Stroes ES, Kastelein JJ.

Circulation. 2008 Dec 9;118(24):2515-22. doi: 10.1161/CIRCULATIONAHA.108.772665. Epub 2008 Nov 24. Erratum in: Circulation. 2009 Feb 10;119(5):e197.

13.

Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver.

Gauthier A, Lau P, Zha X, Milne R, McPherson R.

Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2177-84. Epub 2005 Aug 25.

14.

JTT-705: is there still future for a CETP inhibitor after torcetrapib?

Rennings AJ, Stalenhoef A.

Expert Opin Investig Drugs. 2008 Oct;17(10):1589-97. doi: 10.1517/13543784.17.10.1589 . Review.

PMID:
18808319
15.

Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.

Barter P.

Am J Cardiol. 2009 Nov 16;104(10 Suppl):10E-5E. doi: 10.1016/j.amjcard.2009.09.014.

PMID:
19895939
16.
18.

Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.

Niesor EJ.

Curr Opin Lipidol. 2011 Aug;22(4):288-95. doi: 10.1097/MOL.0b013e3283475e00. Review.

PMID:
21587074
19.

Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?

Neeli H, Rader DJ.

Cardiol Clin. 2008 Nov;26(4):537-46. doi: 10.1016/j.ccl.2008.06.005. Review.

PMID:
18929230
20.

[HDL and CETP in atherogenesis].

Pöss J, Böhm M, Laufs U.

Dtsch Med Wochenschr. 2010 Feb;135(5):188-92. doi: 10.1055/s-0030-1247862. Epub 2010 Jan 15. Review. German.

PMID:
20082258

Supplemental Content

Support Center